Using the GISAID EpiCoV database, we identified 256 COVID-19 patients in Japan during March 31–December 31, 2023, who had mutations in the SARS-CoV-2 nonstructural protein 5 conferring ensitrelvir resistance. Ongoing genomic surveillance is required to monitor emergence of SARS-CoV-2 mutations that are resistant to anticoronaviral drugs.
All Keywords
【저자키워드】 COVID-19, coronavirus disease, severe acute respiratory syndrome coronavirus 2, viruses, respiratory infections, zoonoses, SARS-CoV-2, coronavirus, SARS, antimicrobial resistance, Japan, GISAID, ensitrelvir,
【저자키워드】 COVID-19, coronavirus disease, severe acute respiratory syndrome coronavirus 2, viruses, respiratory infections, zoonoses, SARS-CoV-2, coronavirus, SARS, antimicrobial resistance, Japan, GISAID, ensitrelvir,